Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Solid Biosciences

Evaluate

Thumbnail
October 24, 2022

Syncona sets its sights on a gene therapy turnaround

But, with Applied Genetic Technologies Corporation, can lightning strike a third time?

Thumbnail
July 06, 2022

ICNMD 2022 – still unclear whether Sarepta can accelerate

New data with SRP-9001 look decent, but filing plans remain uncertain.

Article image
Vantage logo
February 24, 2022

Amicus exits gene therapy

Spac backtrack confirms that the gene therapy bubble has burst

Article image
Vantage logo
January 11, 2022

JP Morgan 2022 – Sarepta gets another bite at the gene therapy cherry

But unimpressive phase 2 results, plus a lack of a placebo control arm, raise questions.

Article image
Vantage logo
September 29, 2021

Pfizer adds to gene therapy woes

But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.

Article image
Vantage logo
September 01, 2021

Astellas’s gene therapy aspirations crumble

AT132 has prompted more safety concerns, this time at a lower dose than before.

Article image
Vantage logo
March 29, 2021

Uniqure tries to restore gene therapy calm

Article image
Vantage logo
March 16, 2021

Gene therapy data shake Solid

Better-looking safety might not be enough to get Solid back in the Duchenne muscular dystrophy game.

Article image
Vantage logo
January 08, 2021

Gene therapy trial fails to rectify Sarepta’s sorry record

Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.

Article image
Vantage logo
December 23, 2020

Voyager hold adds to gene therapy woes

Article image
Vantage logo
May 18, 2020

Sarepta gains on Pfizer's setback

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up